Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy

Authors :: Sheila N.J. Sait
Petr Starostik
Eunice S. Wang
Maurice Barcos
Meir Wetzler
Ahmed Abdelhalim
AnneMarie W. Block
Source :: Leukemia & Lymphoma. 48:1053-1056
Publication Year :: 2007
Publisher :: Informa UK Limited, 2007.
Abstract: Dasatinib (DA, Sprycel,® Bristol-Myers Squibb) is an oral tyrosine kinase inhibitor indicated for treatment of patients with chronic myelogenous leukemia and Philadelphia chromosome-positive (Ph+) ...

Subjects :: Cancer Research
Philadelphia Chromosome Positive
medicine.drug_class
business.industry
Hematology
medicine.disease
Tyrosine-kinase inhibitor
Dasatinib
Oncology
hemic and lymphatic diseases
Cancer research
medicine
Central nervous system leukemia
business
Chronic myelogenous leukemia
medicine.drug

Full Text Access

Tools